Results

1–10 of 11 results for biosimilar

Efficacy and Safety of CT-P42 Compared to Reference Aflibercept (AFL) in Diabetic Macular Edema (DME): 24-Week Results From the Phase 3 CT-P42 3.1 Study
David M. Brown, MD
Annual Meeting Talks
2023
Biosimilar Paradox: How Biosimilar Use Will Increase Patient and Healthcare Costs
Ravi Parikh, MD MPH
Annual Meeting Talks
2023
Efficacy and Safety of Biosimilar Ranibizumab-nuna and Ranibizumab-eqrn in Clnical Use by a Consortium of Retina Specialists
Carl C. Awh, MD, FASRS
Annual Meeting Talks
2023
Comparison of Originator and Biosimilar Medications for Pediatric Noninfectious Uveitis
Nita Valikodath, MD, MS
Annual Meeting Talks
2023
Phase III Randomized Clinical Trial Comparing SB15 With Reference Aflibercept in Neovascular Age-Related Macular Degeneration 56-Week Results
Min Sagong, MD
Annual Meeting Talks
2023
Intravitreal Therapeutics Utilization in 2023
Anton M Kolomeyer, MD, PhD
Annual Meeting Talks
2024
Assessment on Pre-to-Post Switching Efficacy and Safety of SB15 (Proposed Aflibercept Biosimilar): Post Hoc Analysis of a Phase 3 Clinical Trial
Srinivas Reddy Sadda, MD
Annual Meeting Talks
2024
Safety and Efficacy of Switching to Biosimilar Ranibizumab in Eyes Initially Treated With Reference Ranibizumab for nAMD, DME, or RVO
Nikhil K Bommakanti, MD
Annual Meeting Talks
2024
Baseline Factors Associated With 1-Year Outcomes in Phase III Comparison of SB11 (Approved Ranibizumab Biosimilar) With Reference Ranibizumab in nAMD
Neil M. Bressler, MD
Annual Meeting Talks
2022
Biosimilars: What Can Retina Learn from Oncology?
Kathy W Oubre, MS
Updates from the Field
2022